An AstraZeneca antibody drug for Covid-19 has clinical data showing the drug reduced the risk of infection by 77%. With the results, the pharmaceutical giant pulls ahead of other companies developing injectable versions of antibody drugs for Covid-19 prevention.
July 1, 2021
July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more.
$550M: VC Fund for Therapeutics for Unmet Needs
venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds. Led by Managing Partners Corey Goodman, Ph.D., Robert Adelman, M.D., Aaron Royston, M.D., and Richard Gaster, M.D., Ph.D., venBio Fund IV will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals
Sutro Biopharma to Participate in Two Virtual Investor Conferences in June prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Emergency authorization of Regeneron Pharmaceuticals’ Covid-19 antibody drug now includes an injectable version, which is a more convenient option for patients. The drug developer plans to seek full FDA approval of its antibody cocktail later this summer.
Zydus Cadila launches ‘Ujvira’ to treat breast cancer
May 24, 2021
Treatment cost to come down by 80% for the patients
In a breakthrough in breast cancer treatment, pharma major Zydus Cadila (Cadila Healthcare Limited) on Monday announced the launch of Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar, which is considered a highly effective drug for treating both early and advanced HER2-positive breast cancer. The company launched the product under the brand name ‘Ujvira’.
The human epidermal growth factor receptor 2 (HER2)-positive breast cancer is considered an aggressive form and constitutes 20 to 25% of all breast cancers, the company informed, adding that its new product can reduce the treatment cost by almost 80 per cent.